[Special Stock] Deepnoid, Bearing Fruit in Medical AI... Overseas Expansion and Domestic Usage Growth

Medical artificial intelligence (AI) company Deepnoid is showing strong performance. Expectations are rising as concrete results emerge in the medical AI sector.

As of 9:30 a.m. on the 31st, Deepnoid is trading at 7,920 KRW, up 4.21% from the previous day.

Recently, Deepnoid signed an MOU to supply the disease diagnosis assistance AI solution ‘DEEP:AI’ with the Philippine Academy of Medical Specialists (PAMS) and De Los Santos Medical Center.

This initiative aims to expand digital healthcare to improve public health in the Philippines. Deepnoid will provide the multi-pulmonary disease diagnosis assistance solution ‘DEEP:CHEST’, the pulmonary nodule diagnosis assistance solution ‘DEEP:LUNG’, and the cerebral aneurysm diagnosis assistance solution ‘DEEP:NEURO’.

The Philippines is one of the countries with significant interest in medical AI. Comprising over 7,600 islands, traveling between islands takes considerable time. By utilizing AI software that assists in disease diagnosis, rapid and highly accurate diagnoses can be made, enabling appropriate treatment. There is a strong need to improve the overall quality of healthcare.

Deepnoid CEO Choi Woo-sik stated, "The Philippines is the medical market we expect the most among Southeast Asian countries," and added, "We received a proposal for a medical AI joint venture from officials of the Philippine Medical Association." He continued, "This was initiated by requests from medical institutions," and said, "We plan to actively conduct sales activities in the promising Philippine medical market."

The fact that the AI-based cerebral aneurysm detection diagnosis assistance solution ‘DEEP:NEURO’ has started being used in medical institutions as a non-reimbursed service under health insurance was also cited as a positive factor. DEEP:NEURO was selected as an innovative medical technology through the integrated review evaluation of innovative medical devices conducted by the Ministry of Food and Drug Safety and the Ministry of Health and Welfare last year. Since then, it has been introduced in 17 hospitals in Korea. Following procedures, it was reported to the Korea Health Industry Development Institute and received the actual usage approval notification titled 'Innovative Medical Technology Usage Report (Clinical Practice) Result Notification.' This is a required process for hospitals using products designated as innovative medical technologies to claim reimbursement or non-reimbursement.